Cerus Corporation (FRA:CU2)

Market Cap	296.91M +24.9%
Revenue (ttm)	175.56M +14.3%
Net Income	-13.31M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	232
Open	1.571
Previous Close	1.517
Day's Range	1.571 - 1.571
52-Week Range	0.990 - 2.462
Beta	n/a
RSI	44.25
Earnings Date	Mar 2, 2026

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma do...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1991
• Employees: 268
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CU2

Financial Performance

In 2025, Cerus's revenue was $206.13 million, an increase of 14.35% compared to the previous year's $180.27 million. Losses were -$15.63 million, -25.29% less than in 2024.

Financial numbers in USD